Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Refractory Polymyositis and Dermatomyositis
NCT02043548Phase 2Completed
- Start
- Oct 2014
- Primary completion
- Jul 2019
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in polymyositis (PM) and dermatomyositis (DM) comparing Tocilizumab with Placebo (2 arms). Primary endpoint: Total Improvement Score at Week 24. Started Oct 2014; status: completed.
02
Drugs
tocilizumab
03
Conditions
polymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on NCT02043548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02043548.